Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 29 min 19 sec ago

Wright Medical Group, Inc. Announces Commercial Launch of INFINITY(R) Total Ankle System

Tue, 06/17/2014 - 12:13
Third Generation System Extends Leadership Position in Treating End-Stage Ankle Arthritis MEMPHIS, Tenn.--(Healthcare Sales & Marketing Network)--Wright Medical Group, Inc. (WMGI) today announced the full U.S. commercial launch of its INFINITY® Tota...
Devices, Orthopaedic, Product Launch
Wright Medical Group, INFINITY Total Ankle, Total Ankle

Regulus Appoints Paul C. Grint, M.D. as Chief Medical Officer

Mon, 06/16/2014 - 14:46
Recognized Industry Leader Brings Extensive Clinical and Product Development Expertise LA JOLLA, Calif., June 16, 2014 -- (Healthcare Sales & Marketing Network) -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company leading the discovery and ...
Biopharmaceuticals, Personnel
Regulus Therapeutics, microRNA

Titan Medical Inc. Announces Completion of Key Milestone in the Development of Its SPORT(TM) Surgical System

Mon, 06/16/2014 - 14:38
TORONTO, ONTARIO--(Healthcare Sales & Marketing Network) - Titan Medical Inc. (the "Company") (TSX VENTURE:TMD)(TITXF) announced today that it successfully completed animal tissue studies on May 30, 2014, performing a full cholecystectomy (gallbl...
Devices, Surgery
Titan Medical, SPORT Surgical System, robotic surgery

Hill-Rom Announces Definitive Agreement To Acquire TRUMPF Medical

Mon, 06/16/2014 - 13:43
Combination Will Enhance Product Portfolio to Create Integrated Operating Room Solutions Provider Diversifies Revenue Stream and Expands Global Footprint Immediately Accretive To Adjusted EPS Company to Host Conference Call Today CHICAGO, June ...
Devices, Mergers & Acquisitions
Hill-Rom Holdings, TRUMPF Medical

Aastrom Announces Strategic Plan for Recently Acquired Cell Therapy and Regenerative Medicine Business

Mon, 06/16/2014 - 13:37
Manufacturing of MACI in Denmark to be discontinued Sales of MACI in Europe, representing 1% of revenues in 2014, temporarily ceased U.S. action plan implemented to optimize R&D, manufacturing and commercial operations Measures expected to enable ...
Regenerative Medicine
Aastrom Biosciences, Sanofi, Epicel

Sunshine Heart Appoints Brian Brown as Senior Vice President of Operations and Technology

Mon, 06/16/2014 - 13:28
EDEN PRAIRIE, Minn., June 16, 2014 -- (Healthcare Sales & Marketing Network) -- Sunshine Heart, Inc. (SSH) today announced the appointment of Brian Brown to the position of Senior Vice President of Operations and Technology. In this capacity, Mr. Brown wil...
Devices, Cardiology, Personnel
Sunshine Heart, C-Pulse Heart Assist

Agena Bioscience Announces FDA 510(k) Premarket Clearance of the IMPACT Dx(TM) Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx(TM) System

Mon, 06/16/2014 - 13:20
IMPACT Dx™ Combined Function System Will Also Be Available in the European Union SAN DIEGO, June 16, 2014 -- (Healthcare Sales & Marketing Network) -- Agena Bioscience, Inc., which recently acquired the Bioscience business of Sequenom, Inc., was notifi...
Diagnostics, FDA
Agena Bioscience, Sequenom, IMPACT Dx, Factor V Leiden

Varian Medical Systems to Equip Prime Healthcare Services Hospitals with Varian Technology for Image-Guided Radiotherapy and Radiosurgery

Fri, 06/13/2014 - 12:57
Prime Healthcare acquires four TrueBeam™ systems as a step toward upgrading and standardizing cancer treatment services across its healthcare system PALO ALTO, Calif., June 13, 2014 -- (Healthcare Sales & Marketing Network) -- Varian Medical Systems (V...
Devices, Oncology
Varian Medical Systems, radiotherapy, radiosurgery, TrueBeam

Ligand Partner GSK Announces Results of Phase 3 PETIT2 Study of Eltrombopag (Promacta(TM)/Revolade(TM)) in Pediatric Patients with Chronic Immune Thrombocytopenia

Fri, 06/13/2014 - 12:48
SAN DIEGO--(Healthcare Sales & Marketing Network)--Ligand Pharmaceuticals Incorporated (LGND) announces that its partner, GlaxoSmithKline (GSK) plc, presented the results from the Phase 3 PETIT2 study evaluating the efficacy of eltrombopag vs. placebo in p...
Biopharmaceuticals
Ligand Pharmaceuticals, GlaxoSmithKline, Eltrombopag, Promacta, Revolade

EntreMed Stockholders Approve Name Change To CASI Pharmaceuticals

Fri, 06/13/2014 - 12:42
Common stock to begin trading under "CASI" on June 16, 2014 ROCKVILLE, Md., June 13, 2014 -- (Healthcare Sales & Marketing Network) -- EntreMed, Inc. (ENMD), a clinical-stage biopharmaceutical company developing therapeutics for the treatment...
Biopharmaceuticals
EntreMed, CASI Pharmaceuticals

Theravance, Inc. Appoints George B. Abercrombie as Senior Vice President, Corporate Partnerships, Commercial

Fri, 06/13/2014 - 12:35
SOUTH SAN FRANCISCO, CA--(Healthcare Sales & Marketing Network) - Theravance, Inc. (NASDAQ: THRX) ("Theravance"), a royalty management company, today announced the appointment of George B. Abercrombie, Senior Vice President, Corporate Partnership...
Biopharmaceuticals, Personnel
Theravance, Glaxo Group

FDA approves Bayer's Gadavist (gadobutrol) Injection as the first magnetic resonance contrast agent for evaluation of breast cancer in the United States

Thu, 06/12/2014 - 18:20
Gadavist-enhanced breast MRI demonstrated superior sensitivity (range: 80-89%) for the presence and extent of malignant disease compared to unenhanced breast MRI (range: 37-73%) Sensitivity for the presence and extent of malignant breast disease ranged ...
Biopharmaceuticals, Radiology, FDA
Bayer HealthCare, Gadavist, gadobutrol, contrast agent, breast cancer

Integra LifeSciences Announces Contract with Premier, Inc.

Thu, 06/12/2014 - 13:42
Will Provide Small Bone Orthopedic Implants PLAINSBORO, N.J., June 12, 2014 -- (Healthcare Sales & Marketing Network) -- Integra LifeSciences Holding Corporation (IART) today announced that its Orthopedics and Tissue Technologies group signed a three-ye...
Devices, Group Purchasing, Orthopaedic
Integra LifeSciences

Clarus Therapeutics Secures $31.5 Million in Financing

Thu, 06/12/2014 - 13:13
Announces New Appointment to Board of Directors NORTHBROOK, Ill., June 12, 2014 -- (Healthcare Sales & Marketing Network) -- Clarus Therapeutics, Inc., a men's health specialty pharmaceutical company focused on the development and commercialization of R...
Biopharmaceuticals, Venture Capital, Personnel
Clarus Therapeutics, REXTORO

Cardiovascular Systems Announces Plans for New Corporate Headquarters

Thu, 06/12/2014 - 13:08
Facility to Accommodate Anticipated Growth Company Will Remain in New Brighton, Minn. ST. PAUL, Minn.--(Healthcare Sales & Marketing Network)--Cardiovascular Systems, Inc. (CSI) (CSII), today announced plans to build a new corporate headquarters in ...
Devices, Interventional Cardiology
Cardiovascular Systems, Orbital Atherectomy

Scioderm Names Ronald Nardi, Ph.D. Chief Scientific Officer

Thu, 06/12/2014 - 13:02
DURHAM, N.C., June 12, 2014 -- (Healthcare Sales & Marketing Network) -- Scioderm, Inc. today announced the addition of Ronald Nardi, Ph.D. as the company's first chief scientific officer. Key points: Dr. Nardi brings more than 35 years of experienc...
Biopharmaceuticals, Personnel
Scioderm, epidermolysis bullosa, SD-101

SoluMatrix(R) Meloxicam Demonstrates Significant Efficacy at 30 Percent Lower Doses in the Treatment of Osteoarthritis

Thu, 06/12/2014 - 12:51
Phase 3 Data Presented at EULAR 2014 PHILADELPHIA--(Healthcare Sales & Marketing Network)--Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today will present Phase 3 results that sho...
Biopharmaceuticals
Iroko Pharmaceuticals, SoluMatrix, meloxicam, osteoarthritis

Aerocrine AB Announces Leadership Changes

Thu, 06/12/2014 - 12:39
SOLNA, Sweden--(Healthcare Sales & Marketing Network)--Aerocrine AB (OMX Nordic Exchange: AERO) today announced that Marshall Woodworth will be appointed new Chief Financial Officer. Anders Murman will be promoted to Chief Technology Officer. Marshall W...
Devices, Personnel
Aerocrine, NIOX MINO, NIOX VERO

Tissue Regenix Announces Launch of DermaPure(TM) in the USA

Thu, 06/12/2014 - 12:35
DermaPure™ targets $1.4 billion a year market for skin substitutes Distribution network now covers 80% of country Federal institution distributor appointed YORK, UNITED KINGDOM--(Healthcare Sales & Marketing Network) - Tissue Regenix Group plc (AI...
Devices, Regenerative Medicine, Wound Care, Product Launch
Tissue Regenix Group, DermaPure, dCELL , tissue scaffold

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong